Heart Failure Medicine approval for Te Arai BioFarma

Heart Failure Medicine approval for Te Arai BioFarma

August 22 2016

A Medicine which is currently not available to New Zealanders through PHARMAC received Medsafe regulatory approval this week.

Eplerenone Te Arai (eplerenone) is used as an adjunct in the management of chronic heart failure. Eplerenone has been well studied and demonstrates a significant survival benefit in people that have heart failure after a heart attack.

Known as an aldosterone receptor antagonist eplerenone is more selective than current treatment options, meaning a lower risk of developing side effects compared to current treatment.

Eplerenone is already available as a funded Medicine in Europe, the UK and Australia.

“We have been working with the government agency PHARMAC towards the funding of Eplerenone Te Arai for New Zealanders. It is a well proven Medicine that other countries have used for years to reduce the risk of cardiovascular death after a heart attack” Lance Gravatt Chairman at Te Arai BioFarma said on Friday following Medsafe approval.

Eplerenone Te Arai has been recommended for funding by PHARMACs clinical advice group PTAC.

Eplerenone Te Arai is a Prescription Medicine. For full information please consult the Medsafe website and product data sheet at www.medsafe.govt.nz Te Arai BioFarma is a New Zealand privately held company created to improve access to new and required Medicines for New Zealanders. For further details contact enquiries@tearaibiofarma.com or 0800 832 724

< Back to News